• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:20:07 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)

     

    EDAP TMS S.A.

    (Name of Issuer)

     

    American Depositary Shares and Ordinary Shares, nominal value €0.13 per share

    (Title of Class of Securities)

     

    268311107**

     

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)
         
      [X] Rule 13d-1(c)
         
      [  ] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 268311107 has been assigned to the American Depositary Shares of the Company, which are quoted on the Nasdaq Global Market under the symbol “EDAP.” Each American Depositary Share represents 1 Ordinary Share.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       
    CUSIP No. 26831110713G/APage 2 of 8 Pages

     

         NAMES OF REPORTING PERSONS
         Opaleye Management Inc.
       
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

       20-5648796

       
         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Massachusetts

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 657,500 American Depositary Shares (“ADS”))
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9

       657,500 Ordinary Shares (represented by 657,500 ADS)

         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    CO

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 3 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       Opaleye, L.P.

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a) [  ]
    2    (b) [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Delaware

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares (represented by 657,500 ADS)
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    657,500 Ordinary Shares (represented by 657,500 ADS)
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    PN

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 4 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       James Silverman

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    United States

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    657,500 Ordinary Shares (represented by 657,500 ADS)
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    657,500 Ordinary Shares (represented by 657,500 ADS)

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    657,500 Ordinary Shares (represented by 657,500 ADS)
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    2.26% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    IN

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 5 of 8 Pages

     

    Item 1(a).   Name of Issuer:
         
        The name of the issuer is EDAP TMS S.A. (the “Company”).
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:
         
        The Company’s principal executive offices are located at Parc Activite La Poudrette Lamartine, 4/6 Rue du Dauphine, 69120 Vaulx-en-Velin, France.
         
    Item 2(a).   Name of Person Filing.
         
        This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the Ordinary Shares of the Company:
         
        Opaleye Fund
         
        Opaleye, L.P. (the “Opaleye Fund”), a private fund formed in the state of Delaware.
         
        Investment Manager
         
       

    Opaleye Management Inc. (the “Investment Manager”), with respect to the Ordinary Shares held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager. The Investment Manager also serves as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. The Investment Manager disclaims beneficial ownership of the shares held by the Managed Account.

         
        Reporting Individual
         
        Mr. James Silverman (the “Reporting Individual”), with respect to the Ordinary Shares held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.
         
    Item 2(b).   Address of Principal Business Office or, if None, Residence.
         
        One Boston Place, 26th Floor
        Boston, Massachusetts 02108
         
    Item 2(c).   Citizenship.
         
        Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
         
    Item 2(d).   Title of Class of Securities.
         
       

    Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) represented by American Depositary Shares (“ADS”), each of which represents one Ordinary Share.

         
    Item 2(e).   CUSIP Number.
         
        There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 268311107 has been assigned to the ADS, which are quoted on the Nasdaq Global Market under the symbol “EDAP”.

     

       
    CUSIP No. 26831110713G/APage 6 of 8 Pages

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) [  ] Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) [  ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     

    (c) [  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) [  ] Investment company registered under Section 8 of the Investment Company Act.
         
    (e) [  ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) [  ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); 
         
    (g) [  ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) [  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i) [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
         
    (j) [  ] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) [  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
       
     

    Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*

      Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
      James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

    (b)Percent of class:
      
     Opaleye Management Inc. — 2.26%**
     

    Opaleye, L.P. — 2.26%**

     

    James Silverman — 2.26%**

     

    * Based upon 29,141,566 Ordinary Shares outstanding on December, 2019 as reported by the Issuer on its annual report on Form 20-F filed with the Securities and Exchange Commission on April 16, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

       
    CUSIP No. 26831110713G/APage 7 of 8 Pages

     

    (c)Number of shares as to which the person has:
        
     (i) Sole power to vote or to direct the vote:
        
       Opaleye Management Inc. — 0 Ordinary Shares
       Opaleye, L.P. — 0 Ordinary Shares
       James Silverman — 0 Ordinary Shares

     

     (ii) Shared power to vote or to direct the vote:
        
       Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

     (iii) Sole power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 0 Ordinary Shares
       Opaleye, L.P. — 0 Ordinary Shares
       James Silverman — 0 Ordinary Shares

     

     (iv) Shared power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       Opaleye, L.P. — 657,500 Ordinary Shares (represented by 657,500 ADS)*
       James Silverman — 657,500 Ordinary Shares (represented by 657,500 ADS)*

     

    * Includes 57,500 Ordinary Shares (represented by 57,500 ADS) held by the Managed Account

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       
    CUSIP No. 26831110713G/APage 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021 By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name:  James Silverman
      Title: Managing Member of Opaleye GP LLC,
        the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

     
     

     

    JOINT FILING AGREEMENT

     

    This Joint Filing Agreement, dated February 12, 2021, is entered into by and among Opaleye Management Inc., a Massachusetts corporation, Opaleye, L.P., a Delaware limited partnership and James Silverman, an individual (collectively referred to herein as (the “Filers”). Each of the Filers may be required to file with the U.S. Securities and Exchange Commission a statement on Schedule 13G with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of the Issuer beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    DATED: February 12, 2021

     

      By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.  
         
      By: /s/ James Silverman
      Name:  James Silverman
      Title: Managing Member of Opaleye GP LLC,
        the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.  
         
      By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

       

    Get the next $EDAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Levine Joshua bought $42,200 worth of shares (10,000 units at $4.22), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:03:23 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

    , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce

    5/29/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

    , May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN, Texas, May 21th, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York. Date: Thursday, June 4th Time: 2:00-2:30 PM ET Format: Presentation and 1x1 investor meetings Webcast: https://event.summitcast.com

    5/21/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

    Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")

    5/15/26 6:30:00 AM ET
    $EDAP
    $PROF
    $TLX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $EDAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Marketing & Product Mgmt. Annen Steven was granted 90,000 shares, increasing direct ownership by 217% to 131,490 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:05:24 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Levine Joshua bought $42,200 worth of shares (10,000 units at $4.22), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:03:23 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Gen Counsel & Corp Secretary Shah Sanket was granted 67,500 shares (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:05:04 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    SEC Filings

    View All

    EDAP TMS S.A. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - EDAP TMS SA (0001041934) (Filer)

    6/1/26 4:05:28 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS S.A. filed SEC Form 8-K: Other Events

    8-K - EDAP TMS SA (0001041934) (Filer)

    5/29/26 7:30:18 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by EDAP TMS S.A.

    DEFA14A - EDAP TMS SA (0001041934) (Filer)

    5/14/26 7:32:39 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EDAP TMS SA downgraded by Piper Sandler

    Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral

    5/15/25 1:10:07 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS SA downgraded by Jefferies with a new price target

    Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

    4/4/25 8:36:35 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on EDAP TMS SA with a new price target

    Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

    11/1/22 6:28:24 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Leadership Updates

    Live Leadership Updates

    View All

    EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

    , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce

    5/29/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP | Focal One to Host Investor Day on June 1, 2026

    , May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU. The event will also cover an overview of the Company's business plans and strategic path forward, including our: Growth Strategy and Long-Term Financial TargetsExpanding Th

    5/13/26 4:30:00 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Announces Appointment of David Horn to Board of Directors

             EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee

    2/12/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Financials

    Live finance-specific insights

    View All

    EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue

    , May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year53% Growth in First Quarter U.S. HIFU Procedures Year-Over-Year83% Growth in First Quarter Focal One Shipments Year-Over-Year Demonstrating Strong MomentumLandmark HIFI-2 Study Results Further Strengthen Focal One Robotic HIFU Market Position AUSTIN, Texas, May 7, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today reported financial results for the first quarter of 2026. "We delivered our strongest HIFU quarter t

    5/7/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

    , April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for c

    4/16/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E

    3/25/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    11/14/24 3:36:33 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/2/24 9:41:45 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/14/23 8:19:52 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care